目录
更新日期:2026年4月15日
姓 名 陆克 性 别
民 族 汉族 导师层次 博士导师
技术职称 研究员 导师类型 学术型
最后学历 博士研究生毕业 最后学位 哲学博士学位
行政职务 其他 Email lu_ke@smu.edu.cn
工作单位 南方医科大学深圳医院 邮政编码 518000
个人简介

 

陆克博士,现任南方医科大学深圳医院骨科PI、骨科医师、博士生导师及博士后合作导师,聚焦以骨/软骨为中心的跨器官诊疗分子机制研究,以肝-骨、软骨-神经互作角度为切入点,创新性解析肝性骨病、骨关节炎、椎间盘退变等多种骨骼系统疾病的分子病理机制,并基于上述互作机制开发新药物分子靶点,持续推动骨骼系统疾病跨器官/组织整合的临床诊疗策略转变,近5年以第一/通讯作者(含共同),在Cell Metabolism, The Innovation, Bioactive Materials(*2),Bone Research (*3)等中科院一区TOP期刊发表论文16篇,其中4篇 IF > 20,累计10篇 IF > 10;获国自然青年科学基金、博士后面上基金(一等)及深圳市自然科学基金等项目累计资助超过700万元;共申请专利9项,其中3项已获授权;荣获2025年度COA骨科基础青年学者比赛全国第二名,2024年度江苏省自然科学奖(二等,第三完成人);受聘担任Journal of Orthopaedic Translation杂志国际编委,Science Bulletin及Gene and Disease杂志青年编委,中国研究型医院学会骨骼系统创新与转化专业委员会常务委员,深圳市数字外科3D打印重点实验室副主任,并成为国际华人骨研协会终身会员。

 

研究领域

1. 组织器官互作的分子机制探索;

2. 慢性骨骼与肝脏疾病的病理表征研究;

3. 生物工程与靶向药物治疗的转化研究。

个人成果

2025年-至今

1) Lu K#, Wei G#, Li G#, Zhang L, Hu YC, Xu G, Wu Z, Sun J, Zhang C, Chen J, Qi L, Wu H, Wu N*, Chen D*. Runx2 mutation plays a key role in the development of scoliosis. The Innovation 2026, 7(3): 101182.   (IF=25.7, JCR分区:Q1,中科院分区:大类1区小类1区)

2) Lu K#, Liao Z#, Li J#, Wang Y, Zhang Y, Cai L, Lu WW, Yang F, Pan H*, Chen D*. MSAB limits osteoarthritis development and progression through inhibition of beta-catenin-DDR2 signaling. Bioact Mater 2025, 46: 259-272. (IF=18.0, JCR分区:Q1,中科院分区:大类1区小类1区)

3) Zhang J#, Li H, Fang G, Zhu Z, Li X, Chen Y, Hou Z, Zhuang W, Liu Y, Wang J, Zhong J, Liu S, Chui EC, Lu WW, Qin L, Cheung WH*, Lu K*, Sang H*. Development of a LASSO dynamic prediction system for interbody cage subsidence following OLIF surgery. NPJ Digit Med. 2025 Nov 13;8(1):656.. (IF=15.2, JCR分区:Q1,中科院分区:大类1区小类1区)

4) Ou J, Zhang J, Alswadeh M, Zhu Z, Tang J*, Sang H*, Lu K*. Advancing osteoarthritis research: the role of AI in clinical, imaging and omics fields. Bone Res 2025, 13(1): 48. ( IF=14.3, JCR分区:Q1,中科院分区:大类1区小类1区)

5) Zhong J, Li W, Li H, Zhang J, Hou Z, Wang X, Zhou E, Lu K*, Zhuang W*, Sang H*. A self-forming bone membrane generated by periosteum-derived stem cell spheroids enhances the repair of bone defects. Acta Biomater 2025, 193: 185-201. (IF=9.4, JCR分区:Q1, 中科院分区:大类1区小类1区)

6) Chen Y#, He P#, Tao S, Zhong J, Jiang K, Hsu Y, Xia G, Mao X*, Sang H*, Lu K*. Injectable sustainable andrographolide-releasing hydrogel for long-lasting alleviation of osteoarthritis and regulation of chondrocyte autophagy via PRKCA/EGFR. Materials Today Bio 2025, 31: 101610.(IF=8.7,JCR分区:Q1,中科院分区:大类1区小类2区)

7) Deng W#, Huang H#, Li J, Xi S, Deng L, Song M, He X, Yao Y, Wang Z, Lu K*, Wu D*, Liu R*, Cai L*. Radiation-Triggered Alkyl Free Radical Generator for the Oxygen-Independent Radioimmunotherapy of Triple-Negative Breast Cancer. ACS Appl Mater Interfaces. 2025 Oct 22;17(42):57919-57935.(IF=8.5,JCR分区:Q1,中科院分区:大类2区小类2区)

2024

5) Lu K#, Zhang M#, Qin H, Shen S, Song H, Jiang H, Zhang C, Xiao G, Tong L, Jiang Q, Chen D*. Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma. Acta Pharmaceutica Sinica B 2024, 14(7): 2977-2991. (IF=14.7, JCR分区:Q1, 中科院分区:大类1区小类1区)

2023

6) Lu K.#, Wang Q.#, Hao L., Wei G., Wang T., Lu W. W., Xiao G., Tong L., Zhao X.*, Chen D*. miR-204 ameliorates osteoarthritis pain by inhibiting SP1-LRP1 signaling and blocking neuro-cartilage interaction. Bioactive Materials 2023, 26: 425-436. (IF=18.0, JCR分区:Q1,中科院分区:大类1区小类1区)

7) Lu K., Wang Q., Jiang H., Li J., Yao Z., Huang Y., Chen J., Zhang Y., Xiao G., Hu X., Luo Z., Yang L., Tong L., Chen D*. Upregulation of beta-catenin signaling represents a single common pathway leading to the various phenotypes of spinal degeneration and pain. Bone Research 2023, 11(1): 18.( IF=14.3, JCR分区:Q1,中科院分区:大类1区小类1区)

8) Wei G.#, Lu K.#, Umar M., Zhu Z., Lu W. W., Speakman J. R., Chen Y., Tong L.*, Chen D*. Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms. Bone Research 2023, 11(1): 63. (IF=14.3, JCR分区:Q1, 中科院分区:大类1区小类1区)

9) Lu K., Zhang M., Wei G., Xiao G., Tong L., Chen D*. Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability. eLife 2023, 12.( IF=6.4, JCR分区:Q1, 中科院分区:大类1区小类1区)

2022

10) Lu K.#, Shi T. S.#, Shen S. Y., Shi Y., Gao H. L., Wu J., Lu X., Gao X., Ju H. X., Wang W., Cao Y., Chen D.*, Li C. J. *, Xue B. *, Jiang Q. *Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. Cell Metabolism 2022, 34(3): 441-457 e447. (IF=27.7,JCR分区:Q1;中科院分区:大类1区小类1区)

11) Lu K.#, Shen S. Y.#, Luo O. Y., Lu Y., Shi T. S., Wu J., Cheng Q., Teng H. J., Chen D., Lu X., Li C. J. *, Jiang Q. *, Fang L. *, Xue B*. Manipulating PP2Acalpha-ASK-JNK signaling to favor apoptotic over necroptotic hepatocyte fate reduces the extent of necrosis and fibrosis upon acute liver injury. Cell Death & Disease 2022, 13(11): 985. (IF=8.1,JCR分区:Q1,中科院分区:大类1区小类2区)

12) Lu K#, Ma F#, Yi D, Yu H, Tong LP, Chen D*. Molecular signaling in temporomandibular joint osteoarthritis. Journal of Orthopaedic Translation 2022, 32: 21-27.(IF=5.9,JCR分区:Q1,中科院分区:大类1区小类1区)